Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Proprotein convertase subtilisin/kexin type 9 (PCSK9) is highly expressed in most cancers, correlating with poor prognosis. Inhibiting PCSK9 enhances anti-tumor immunity by increasing dendritic cell infiltration and MHC-II expression, improving vaccine efficacy.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low-density lipoprotein receptor (LDLR) and is implicated in tumor development.
- PCSK9's comprehensive role across various cancers and its potential as a therapeutic target remain underexplored.
Purpose Of The Study
- To conduct a pan-cancer analysis of PCSK9's oncogenic and immunoregulatory roles.
- To evaluate the efficacy of PCSK9 inhibition in combination with cancer vaccines.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) dataset to analyze PCSK9 expression in 33 tumor types.
- Assessed PCSK9 inhibition effects on tumor immune microenvironment using in vitro cell coculture and mouse models.
- Verified the antitumor efficacy of combined PCSK9 targeting and OVA-II vaccines.
Main Results
- PCSK9 is highly expressed in most tumors, associated with advanced stage and poor prognosis.
- PCSK9 inhibition upregulates dendritic cell infiltration and MHC-II expression, enhancing CD8+ T cell activation.
- Combination therapy of PCSK9 inhibitors and OVA-II vaccines demonstrated potent tumor control.
Conclusions
- PCSK9 plays critical oncogenic and immunoregulatory roles across diverse cancers.
- Targeting PCSK9 enhances anti-tumor immunity and improves the efficacy of cancer vaccines.
- PCSK9 inhibition represents a promising strategy for cancer immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...